Identification of Candidate Tumor Suppressor Genes Inactivated by Promoter Methylation in Melanoma

被引:59
作者
Bonazzi, Vanessa F. [1 ]
Irwin, Darryl [1 ]
Hayward, Nicholas K. [1 ]
机构
[1] Queensland Inst Med Res, Oncogenom Lab, Herston, Qld 4029, Australia
关键词
TAZAROTENE-INDUCED GENE-1; PROTEIN P53-INDUCED NUCLEAR-PROTEIN-1; CUTANEOUS MALIGNANT-MELANOMA; DNA METHYLATION; CDKN2A MUTATIONS; DECREASED EXPRESSION; GERMLINE MUTATIONS; MASS-SPECTROMETRY; BRAF MUTATIONS; RAS MUTATIONS;
D O I
10.1002/gcc.20615
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor suppressor genes (TSGs) are sometimes inactivated by transcriptional silencing through promoter hypermethylation. To identify novel methylated TSGs in melanoma, we carried out global mRNA expression profiling on a panel of 12 melanoma cell lines treated with a combination of 5-Aza-2-deoxycytidine (5AzadC) and an inhibitor of histone deacetylase, Trichostatin A. Reactivation of gene expression after drug treatment was assessed using Illumina whole-genome microarrays. After qRT-PCR confirmation, we followed up 8 genes (AKAP12, ARHGEF16, ARHGAP27, ENC1, PPP1R3C, PPP1R14C, RARRES1, and TPS3INP1) by quantitative DNA methylation analysis using mass spectrometry of base-specific cleaved amplification products in panels of melanoma cell lines and fresh tumors. PPP1R3C, ENC1, RARRES1, and TP531NP1, showed reduced mRNA expression in 35-59% of the melanoma cell lines compared to melanocytes and which was correlated with a high proportion of promoter methylation (>40-60%). The same genes also showed extensive promoter methylation in 6-25% of the tumor samples, thus confirming them as novel candidate TSGs in melanoma. (C) 2008 Wiley-Liss, Inc.
引用
收藏
页码:10 / 21
页数:12
相关论文
共 63 条
[1]   Sporadic multiple primary melanoma cases:: CDKN2A germline mutations with a founder effect [J].
Auroy, S ;
Avril, MF ;
Chompret, A ;
Pham, D ;
Goldstein, AM ;
Bianchi-Scarrá, G ;
Frebourg, T ;
Joly, P ;
Spatz, A ;
Rubino, C ;
Demenais, F ;
Bressac-de Paillerets, B .
GENES CHROMOSOMES & CANCER, 2001, 32 (03) :195-202
[2]   Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer [J].
Baylin, SB ;
Esteller, M ;
Rountree, MR ;
Bachman, KE ;
Schuebel, K ;
Herman, JG .
HUMAN MOLECULAR GENETICS, 2001, 10 (07) :687-692
[3]   The melanoma epidemic:: Res ipsa loquitur [J].
Beddingfield, FC .
ONCOLOGIST, 2003, 8 (05) :459-465
[4]  
Bishop DT, 2002, J NATL CANCER I, V94, P894, DOI 10.1093/jnci/94.12.894
[5]  
Brose MS, 2002, CANCER RES, V62, P6997
[6]   Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer [J].
Cameron, EE ;
Bachman, KE ;
Myöhänen, S ;
Herman, JG ;
Baylin, SB .
NATURE GENETICS, 1999, 21 (01) :103-107
[7]   Differential gene expression in CD3ε- and RAG1-deficient thymuses:: definition of a set of genes potentially involved in thymocyte maturation [J].
Carrier, A ;
Nguyen, C ;
Victorero, G ;
Granjeaud, S ;
Rocha, D ;
Bernard, K ;
Miazek, A ;
Ferrier, P ;
Malissen, M ;
Naquet, P ;
Malissen, B ;
Jordan, BR .
IMMUNOGENETICS, 1999, 50 (5-6) :255-270
[8]  
Castellano M, 1997, CANCER RES, V57, P4868
[9]   Genomic profiling of CpG methylation and allelic specificity using quantitative high-throughput mass spectrometry: critical evaluation and improvements [J].
Coolen, Marcel W. ;
Statham, Aaron L. ;
Gardiner-Garden, Margaret ;
Clark, Susan J. .
NUCLEIC ACIDS RESEARCH, 2007, 35 (18)
[10]   Trends for in situ and invasive melanoma in Queensland, Australia, 1982-2002 [J].
Coory, M ;
Baade, P ;
Aitken, J ;
Smithers, M ;
McLeod, GRC ;
Ring, I .
CANCER CAUSES & CONTROL, 2006, 17 (01) :21-27